{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pyelonephritis-acute/management/management/","result":{"pageContext":{"chapter":{"id":"30a86df1-8159-5bcc-9187-aa647071eeab","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field e8ea7520-21a5-473d-9317-44d57fa58b62 --><h2>Scenario: Management of acute pyelonephritis</h2><!-- end field e8ea7520-21a5-473d-9317-44d57fa58b62 -->","summary":"Covers management of people with acute pyelonephritis, including the decision to treat in primary care or admit to secondary care.","htmlStringContent":"<!-- begin item 8cb6ccf0-5ac3-4c54-8932-2529c7d2e4a3 --><!-- begin field 2bc5a994-7816-40a6-978e-acbc0155e76b --><p>From age 16 years onwards.</p><!-- end field 2bc5a994-7816-40a6-978e-acbc0155e76b --><!-- end item 8cb6ccf0-5ac3-4c54-8932-2529c7d2e4a3 -->","topic":{"id":"1ee909c1-6785-5b3a-a71f-c675db878f51","topicId":"44207967-66bd-4750-aa84-8d9a53c85df0","topicName":"Pyelonephritis - acute","slug":"pyelonephritis-acute","lastRevised":"Last revised in November 2020","chapters":[{"id":"02ed8486-e946-512b-82a2-668a9ff16030","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"46426ef8-dbce-5314-8014-895736033f59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e0c98a4b-654e-5b3d-acbe-7af83e06b09e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d957e39c-6b0e-5ab2-b109-25b3d89f2a69","slug":"changes","fullItemName":"Changes"},{"id":"ac7d383b-749f-5a71-b1a3-64b8ee85c6e4","slug":"update","fullItemName":"Update"}]},{"id":"d8333a3b-c658-5cb9-8d52-f4731cb7591a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"82a178c6-fb1b-55a0-8fff-db47a9a4e56f","slug":"goals","fullItemName":"Goals"},{"id":"528ddc23-f69e-558e-a643-3efdf3ed0c46","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"251eeb06-8579-5cc4-8e1a-95f1d66519b7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f66a975d-d6fb-5db8-9b28-8efc292c4f13","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b5e9e7df-f433-574c-9008-725e03502836","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0a10e02-7199-5bc4-858a-f5b264b68ca3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"86ae3b5d-e5ac-595b-9ce2-6bd39b36e14d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"56a59908-ef99-57a5-94c0-91567fd0c3c3","slug":"definition","fullItemName":"Definition"},{"id":"ec53872e-9c88-566c-bda0-5c8be69f09ba","slug":"causes","fullItemName":"Causes"},{"id":"73f19a3b-6441-55c5-81ba-0912f3b42a15","slug":"complications","fullItemName":"Complications"},{"id":"17fd8038-ffd8-57e6-aa5e-f86def547e29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"235cbfdb-ded5-56f1-8b79-6e33631422d9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ca15553-84c0-5297-abd9-5141ab1dbec6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ede39de9-ed86-5d54-8a0d-82bf548356a4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"2c226c8f-c4ef-59ed-828e-590f38c1719c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3f5167b2-e2ea-5d21-93ef-3ed426750dea","fullItemName":"Management","slug":"management","subChapters":[{"id":"30a86df1-8159-5bcc-9187-aa647071eeab","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"db7647fb-c954-543c-ac60-d09f69832f7e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"93430c57-39bc-5b8b-b176-44cccba23928","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"d385ea3c-fa24-5d51-8bf6-b1372c9fdf3c","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f429e0c9-ab9b-5885-b171-ea841f15722e","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"df1e11c6-9e97-5899-b2b9-0eac5877ab4c","slug":"trimethoprim","fullItemName":"Trimethoprim"}]},{"id":"936e6198-43d8-5e72-be82-c2c59705ea07","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2b045a54-20ef-5b6e-8003-81b3052b42a8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bf21ee38-5a2a-5700-bfd5-24b5084b8cbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4a868f34-40b1-5196-97ec-2b8334024394","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5d08cf27-dc02-5eea-b5c3-b6308f0d1374","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"11dfcefc-cdc3-5c3f-aeea-da5c0be2ebaa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5cc5db18-4c4f-5e6e-9169-72968b0e3705","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f7685686-568f-5174-afd7-a7778a4f2716","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3f5167b2-e2ea-5d21-93ef-3ed426750dea","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"d9a40a57-2d6c-52b7-8c18-846c0d5d09cb","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field b2d49e27-7d3f-4387-9334-a99d00e2faa4 --><h3>When should I refer people with acute pyelonephritis? </h3><!-- end field b2d49e27-7d3f-4387-9334-a99d00e2faa4 -->","summary":null,"htmlStringContent":"<!-- begin item 82bfb6cc-325b-434d-af35-a99d00e2e52c --><!-- begin field f48ca88a-e657-44b6-a0f6-a99d00e2faa4 --><ul><li><strong>Admit people to hospital if they have any symptoms or signs suggesting a more serious illness or condition (for example, sepsis).</strong></li><li><strong>Consider referring or seeking specialist advice for people with acute pyelonephritis if they:</strong> <ul><li>Are significantly dehydrated or unable to take oral fluids and medicines.</li><li>Are pregnant.</li><li>Have a higher risk of developing complications — people with known or suspected structural or functional abnormality of the genitourinary tract or underlying disease (such as diabetes mellitus, or immunosuppression).</li><li>Have recurrent episodes of UTI (for example, two or more episodes in a 6-month period).</li></ul></li><li><strong>Also consider referral for:</strong><ul><li>Men, following a single episode without an obvious cause. </li><li>Women with recurrent pyelonephritis. </li></ul></li><li><strong>Refer</strong><strong> urgently using a suspected cancer pathway referral for an appointment within 2 weeks for people</strong>: <ul><li>Aged 45 years and over who have unexplained visible haematuria without urinary tract infection, or visible haematuria that persists or recurs after successful treatment of urinary tract infection.</li><li>Aged 60 years and over who have unexplained non-visible haematuria and either dysuria or a raised white cell count on a blood test.</li></ul></li><li>Consider non-urgent referral for bladder cancer in people aged 60 years and over with recurrent or persistent unexplained UTI. </li><li>For more information on when to suspect a urological cancer, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/urological-cancers-recognition-referral/\">Urological cancers - recognition and referral</a>. </li></ul><!-- end field f48ca88a-e657-44b6-a0f6-a99d00e2faa4 --><!-- end item 82bfb6cc-325b-434d-af35-a99d00e2e52c -->","subChapters":[{"id":"eda2514d-b593-5bce-ae67-f85676ced97e","slug":"basis-for-recommendation-2e3","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 331e393f-c297-4ee9-b83e-a99d00e2faa6 --><h4>Basis for recommendation</h4><!-- end field 331e393f-c297-4ee9-b83e-a99d00e2faa6 -->","summary":null,"htmlStringContent":"<!-- begin item 2e313fdb-1839-471a-899e-a99d00e2faa6 --><!-- begin field a85242df-bcd8-47d5-8e8f-a99d00e2faa6 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Pyelonephritis (acute): antimicrobial prescribing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">NICE, 2018a</a>], <em>Urinary tract infection (recurrent): antimicrobial prescribing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">NICE, 2018e</a>], <em>Suspected cancer: recognition and referral </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">NICE, 2017</a>], the Quality Standard <em>Urinary tract infections in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">NICE, 2015</a>], expert opinion in a narrative review <em>Pyelonephritis can lead to life-threatening complications</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">Keenan, 2017</a>], the European Association of Urology (EAU) guideline <em>Urological infections </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">EAU, 2018</a>], and what CKS considers good clinical practice.</p><h5>Referral to secondary care </h5><ul><li>NICE recommends reassessing people with pyelonephritis if symptoms worsen at any time, or do not start to improve within 48 hours of taking the antibiotic, and considering referral in people if they [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">NICE, 2018a</a>]:<ul><li>Are significantly dehydrated or unable to take oral fluids and medicines.</li><li>Are pregnant.</li><li>Have a higher risk of developing complications — people with known or suspected structural or functional abnormality of the genitourinary tract or underlying disease (such as diabetes mellitus, or immunosuppression).</li></ul></li><li>Expert opinion in a review article advises that if people have not improved within 48 hours of starting antimicrobial treatment they should be referred to secondary care, except where the infecting pathogen is not susceptible to the agent originally used, an alternative appropriate antibiotic is available, and the patient clinically remains well enough for community care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">Keenan, 2017</a>]. </li><li>The COMPASS therapeutic notes bulletin <em>Bacterial urinary tract infections in primary care</em> advises that admission to hospital should also be considered for people who do not respond to antibiotics within 24 hours (due to antibiotic resistance) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">COMPASS, 2012</a>].</li><li>Patients who fully recover from a single episode of acute pyelonephritis do not need referral to secondary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">Keenan, 2017</a>].  <ul><li>Women with recurrent pyelonephritis and men with a single episode without obvious cause should be referred to urology for a specialist opinion and investigation of possible urological abnormalities.</li></ul></li><li>However, SIGN recommends that all men with upper urinary tract infections (UTI) are referred for urological investigation to ensure that any possible abnormalities are diagnosed and treated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">NICE, 2015</a>] and the NICE quality statement for UTI advises that UTI can indicate the presence of lower urinary tract abnormalities. It is important that men with symptoms of an upper UTI have urological investigations to ensure that any possible abnormalities are diagnosed and treated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">NICE, 2015</a>]. </li></ul><!-- end field a85242df-bcd8-47d5-8e8f-a99d00e2faa6 --><!-- end item 2e313fdb-1839-471a-899e-a99d00e2faa6 -->","subChapters":[]}]},{"id":"2fad100c-708b-55ab-b5a0-ef9f65fe0245","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 0835d74f-0d14-4321-bfcd-a03ca2ff2be0 --><h3>How should I manage a person with suspected acute pyelonephritis in primary care?</h3><!-- end field 0835d74f-0d14-4321-bfcd-a03ca2ff2be0 -->","summary":null,"htmlStringContent":"<!-- begin item 5d8670d1-4d0a-425d-876d-0d67155807d4 --><!-- begin field db0bbeb2-b26b-404f-a838-b9030a7c4e11 --><ul><li><strong>Admit people with acute pyelonephritis to hospita</strong><strong>l if it is severe, or they have any signs or symptoms which suggest a more serious illness or condition</strong>, for example, sepsis. <ul><li>Signs of sepsis, include:<ul><li>Significant tachycardia, hypotension, or breathlessness.</li><li>Marked signs of illness (such as impaired level of consciousness, perfuse sweating, rigors, pallor, significantly reduced mobility).</li><li>A temperature greater than 38°C or less than 36°C.</li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/neutropenic-sepsis/\">Neutropenic sepsis</a>.</li></ul></li></ul></li><li><strong>For all other people, offer an antibiotic, </strong>taking into account: <ul><li>The severity of symptoms.</li><li>The risk of developing complications, which is higher in people with known or suspected structural or functional abnormality of the genitourinary tract or immunosuppression.</li><li>Previous urine culture and susceptibility results.</li><li>Previous antibiotic use, which may have led to resistant bacteria.</li></ul></li><li><strong>For women who are not pregnant, men, and people with indwelling catheters, take account of local antimicrobial resistance data, and</strong> <strong>prescribe either of the following first line options: </strong><ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/pyelonephritis-acute/prescribing-information/cefalexin/\">Cefalexin</a> 500mg twice or three times a day (up to 1– 1.5g three or four times a day for severe infections) for 7-10 days.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/pyelonephritis-acute/prescribing-information/co-amoxiclav/\">Co-amoxiclav</a> (only if appropriate in line with culture and sensitivity results) 500/125 mg three times a day for 7-10 days.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/pyelonephritis-acute/prescribing-information/trimethoprim/\">Trimethoprim</a> (only if appropriate in line with culture and sensitivity results) 200mg twice a day for 14 days.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/pyelonephritis-acute/prescribing-information/ciprofloxacin/\">Ciprofloxacin</a> 500 mg twice a day for 7 days. </li></ul></li><li><strong>For pregnant women who do <em>not </em>require admission, prescribe</strong>:<ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/pyelonephritis-acute/prescribing-information/cefalexin/\">Cefalexin</a> <strong> </strong>500mg twice or three times a day (up to 1– 1.5g three or four times a day for severe infections) for 7-10 days.</li></ul></li><li><strong>For people with indwelling urinary catheters:</strong><ul><li>Check that the catheter is correctly positioned, drains correctly and is not blocked.   </li><li>Consider removing or, if this cannot be done, changing the catheter as soon as possible if it has been in place for more than 7 days.<ul><li>Do not allow catheter removal or change to delay antibiotic treatment. </li><li>Do not give antibiotic prophylaxis for catheter changes unless the person has a history of symptomatic UTIs due to catheter change.</li></ul></li></ul></li><li><strong>Provide appropriate <a class=\"topic-reference internal-reference\" href=\"/topics/pyelonephritis-acute/management/management/#information-advice\">information and advice</a>.</strong></li><li><strong>Review culture and sensitivity results </strong>when they become available, and change the antibiotic if indicated. If the bacteria are resistant and symptoms are not already improving, use a narrow-spectrum antibiotic wherever possible. </li><li><strong>Reassess the person if symptoms worsen at any time, or do not start to improve within 48 hours of taking the antibiotic,</strong> and consider: <ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/pyelonephritis-acute/diagnosis/differential-diagnosis/\">Other possible diagnoses</a>. </li><li>Any symptoms or signs suggesting a more serious illness or condition, such as sepsis. </li><li>Whether previous antibiotic use may have led to resistant bacteria.</li><li>Whether <a class=\"topic-reference internal-reference\" href=\"/topics/pyelonephritis-acute/management/management/#referral\">referral</a> for specialist urological assessment is needed.</li></ul></li></ul><!-- end field db0bbeb2-b26b-404f-a838-b9030a7c4e11 --><!-- end item 5d8670d1-4d0a-425d-876d-0d67155807d4 -->","subChapters":[{"id":"3cf12b3a-da8a-5278-991a-de44dd8d1a3a","slug":"information-advice","fullItemName":"Information and advice","depth":4,"htmlHeader":"<!-- begin field b8b499a7-8e48-4562-868f-a99d00afcb16 --><h4>What information and advice should I provide to people with pyelonephritis?</h4><!-- end field b8b499a7-8e48-4562-868f-a99d00afcb16 -->","summary":null,"htmlStringContent":"<!-- begin item 62cdda47-c1e1-43ce-a252-a99d00afcac9 --><!-- begin field bb6338e5-90b3-4889-833c-a99d00afcb16 --><ul><li><strong>Explain how to take a mid-stream urine sample </strong>— direct the person to information on the NHS website <a data-hyperlink-id=\"dc031485-7a6f-487b-b93d-a999009ffa56\" href=\"https://www.nhs.uk/common-health-questions/infections/how-should-i-collect-and-store-a-urine-sample/\">How should I collect and store a urine sample?</a>. </li><li><strong>Give people advice about: </strong><ul><li>Possible adverse effects of the antibiotic, particularly diarrhoea and nausea.<ul><li>Nausea with vomiting may also be a possible indication of worsening pyelonephritis.</li></ul></li><li>When to seek medical help — for example if symptoms worsen at any time, do not start to improve within 48 hours of taking the antibiotic, or if they become systemically very unwell.</li></ul></li><li><strong>Advise people to: </strong><ul><li>Use paracetamol for pain, or if preferred and suitable, ibuprofen if required.</li><li>Drink sufficient fluids to avoid dehydration.</li></ul></li></ul><!-- end field bb6338e5-90b3-4889-833c-a99d00afcb16 --><!-- end item 62cdda47-c1e1-43ce-a252-a99d00afcac9 -->","subChapters":[]},{"id":"be7a9377-e3c6-5403-bb41-b4e23d8cdc90","slug":"basis-for-recommendation-4fa","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 82cee160-a9d3-48a6-b94b-f159f61c9f01 --><h4>Basis for recommendation</h4><!-- end field 82cee160-a9d3-48a6-b94b-f159f61c9f01 -->","summary":null,"htmlStringContent":"<!-- begin item 4fa00340-d203-4fb8-a58f-3e02eb1229a7 --><!-- begin field aeb9ff9c-b3ee-4294-94e3-19f6721a1c40 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Urinary tract infection (catheter-associated): antimicrobial prescribing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">NICE, 2018b</a>], <em>Pyelonephritis (acute): antimicrobial prescribing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">NICE, 2018a</a>], Public Health England (PHE) guide <em>Diagnosis of urinary tract infections: quick reference tool for primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">PHE, 2018</a>], and what CKS considers good clinical practice.</p><!-- end field aeb9ff9c-b3ee-4294-94e3-19f6721a1c40 --><!-- end item 4fa00340-d203-4fb8-a58f-3e02eb1229a7 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}